Evidence map›Paper›PMID 33428613›Full record

ArticlePloS one2021

Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).

Hideki Tokunaga, Keita Iida, Atsushi Hozawa, Soichi Ogishima, Yoh Watanabe, Shogo Shigeta, Muneaki Shimada, Yumi Yamaguchi-Kabata, Shu Tadaka, Fumiki Katsuoka and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Landscape of germlineFrontiers in oncology · 2023
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Hideki TokunagaDepartment of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Keita IidaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Atsushi HozawaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Soichi OgishimaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan.
Yoh WatanabeDepartment of Obstetrics and Gynecology, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Shogo ShigetaDepartment of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Muneaki ShimadaDepartment of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yumi Yamaguchi-KabataTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Shu TadakaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.ORCID 0000-0002-8256-0735
Fumiki KatsuokaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.ORCID 0000-0003-0939-7887
Shin ItoTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Kazuki KumadaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan.
Yohei HamanakaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Nobuo FuseTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Kengo KinoshitaAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan.
Masayuki YamamotoAdvanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, Sendai, Japan.
Nobuo YaegashiDepartment of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Jun YasudaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.ORCID 0000-0002-3887-6871
Tohoku University · JPTohoku Medical and Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of the population frequencies of definitely pathogenic germline variants in two major hereditary breast and ovarian cancer syndrome (HBOC) genes, BRCA1/2, is essential to estimate the number of HBOC patients. In addition, the identification of moderately penetrant HBOC gene variants that contribute to increasing the risk of breast and ovarian cancers in a population is critical to establish personalized health care. A prospective cohort subjected to genome analysis can provide both sets of information. Computational scoring and prospective cohort studies may help to identify such likely pathogenic variants in the general population. We annotated the variants in the BRCA1 and BRCA2 genes from a dataset of 3,552 whole-genome sequences obtained from members of a prospective cohorts with genome data in the Tohoku Medical Megabank Project (TMM) with InterVar software. Computational impact scores (CADD_phred and Eigen_raw) and minor allele frequencies (MAFs) of pathogenic (P) and likely pathogenic (LP) variants in ClinVar were used for filtration criteria. Familial predispositions to cancers among the 35,000 TMM genome cohort participants were analyzed to verify the identified pathogenicity. Seven potentially pathogenic variants were newly identified. The sisters of carriers of these moderately deleterious variants and definite P and LP variants among members of the TMM prospective cohort showed a statistically significant preponderance for cancer onset, from the self-reported cancer history. Filtering by computational scoring and MAF is useful to identify potentially pathogenic variants in BRCA genes in the Japanese population. These results should help to follow up the carriers of variants of uncertain significance in the HBOC genes in the longitudinal prospective cohort study.

Indexed as

AdultAllelesBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsCohort StudiesDatabases, GeneticFemaleGene FrequencyGenes, BRCA1Genes, BRCA2Genetic Predisposition to DiseaseGenetic TestingGerm-Line MutationHereditary Breast and Ovarian Cancer SyndromeHeterozygoteBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, human

Identifiers

PMID33428613
PMCPMC7799847
OpenAlexW3120251128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.